ASPG and extranodal nasal NK/T cell lymphoma: In the phase II study from France [32], the median survival time was 12.2 months in 19 relapsed/refractory NKTCL patients (12 patients at AA stage I/II) treated with the AspaMetDex regimen (L-asparaginase, methotrexate, and dexamethasone) and with HSCT in two patients.